Guidelines of the DGAI on allergic rhinoconjunctivitis;Leitlinie der DGAI zur allergischen rhinokonjunktivitis

Allergologie

Volumn 26, Issue 4, 2003, Pages 147-162

  Bachert, C ^a   Borchard, U ^b   Wedi, B ^b   Klimek, L ^b   Rasp, G ^b   Riechelmann, H ^b   Schultze Werninghaus, G ^b   Wahn, U ^b   Ring, J ^b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b NONE

Author keywords

Allergic rhinitis; Classification; Diagnosis; Guidelines; Therapy

Indexed keywords

ANTIHISTAMINIC AGENT; BECLOMETASONE DIPROPIONATE; BETAMETHASONE; BUDESONIDE; CHEMOKINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CROMOGLYCATE DISODIUM; CYTOCHROME P450 3A; CYTOKINE; DECONGESTIVE AGENT; DEXAMETHASONE; FLUNISOLIDE; FLUOCORTIN BUTYL; FLUTICASONE PROPIONATE; GLUCOCORTICOID; HYDROCORTISONE; IMMUNOGLOBULIN E; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHYLPREDNISOLONE; MOMETASONE FUROATE; NEDOCROMIL; PREDNISOLONE; TRIAMCINOLONE ACETONIDE;

ALLERGIC RHINITIS; ANAMNESIS; COMORBIDITY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; HUMAN; IMMUNOTHERAPY; IN VITRO STUDY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PROVOCATION TEST; QUALITY OF LIFE; REVIEW; RHINOCONJUNCTIVITIS; SYMPTOM;

EID: 0037717176     PISSN: 03445062     EISSN: None     Source Type: Journal    
DOI: 10.5414/alp26147     Document Type: Review

References (85)

1. Bousquet J., P. van Cauwenberge, N. Khaltaev et al.: (C. Bachert). Management of allergic rhinitis and its impact on asthma (ARIA). J. Allergy Clin. Immunol. 108, S147-334 (2001).
2. Pariente P.D., C. LePen, F. Los, J. Bousquet: Quality-of-life outcomes and the use of antihistamines in a French national population-based sample of patients with perennial rhinitis. Pharmacoeconomics 12, 585-595 (1997).
3. Ring J., J. Wenning: Weißbuch: Allergie in Deutschland 2000. Deutsche Gesellschaft für Allergologie und klinische Immunologie. Urban und Vogel, München 2000.
4. Statistisches Bundesamt: Gesundheitsbericht für Deutschland. Spezialbericht Allergien. Metzler-Poeschel, Stuttgart 2000.
5. Klimek L., M. Reichenbach, T. Mewes, W. Mann: Untersuchungen zur Reproduzierbarkeit und jahreszeitlichen Abhängigkeit von spezifischen intranasalen Provokationstests bei Birkenpollenallergikern. Laryngorhinootologie 76, 475-479 (1997).
6. Connell J.T.: Quantitative intranasal pollen challenges. 3. The priming effect in allergic rhinitis. J. Allergy 43, 33-44 (1969).
7. Ciprandi G., S. Buscaglia, G. Pesce, C. Pronzato, V. Ricca, S. Parmiani, M. Bagnasco: Minimal persistent inflammation is present at mucosal level in patients with asymptomatic rhinitis and mite allergy. J. Allergy Clin. Immunol. 96, 971-979 (1995).
8. Craig T.J., S. Teets, E.B. Lehman, V.M. Chinchilli, C. Zwillich: Nasal congestion secondary to allergic rhinitis as a cause of sleep disturbance and daytime fatigue and the response to topical nasal corticosteroids. J. Allergy Clin. Immunol. 101, 633-637 (1998).
9. Vuurman E.F., L.M. van Veggel, M.M. Uiterwijk, D. Leutner, J.F. O'Hanlon: Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann. Allergy. 71, 121-126 (1993).
10. Lack G.: Pediatric allergic rhinitis and comorbid disorders. J. Allergy Clin. Immunol. 108 (Suppl. 1), 89-815 (2001).
11. Wright A.L., C.J. Holberg, F.D. Martinez, M. Halonen, W. Morgan, L.M. Taussig: Epidemiology of physician-diagnosed allergic rhinitis in childhood. Pediatrics 94, 895-901 (1994).
12. Leynaert B., J. Bousquet, C. Neukirch, R. Liard, F. Neukirch: Perennial rhinitis: an independent risk factor for asthma in nonatopic subjects: results from the European Community Respiratory Health Survey. J. Allergy Clin. Immunol. 104, 301-304 (1999).
13. Ruoppi P., J. Seppa, J. Nuutinen: Acute frontal sinusitis: etiological factors and treatment outcome. Acta Otolaryngol. 113, 201-205 (1993).
14. Keith P.K., M. Conway, S. Evans, D.A. Wong, G. Jordana, D. Pengelly, J. Dolovich: Nasal polyps: effects of seasonal allergen exposure. J. Allergy Clin. Immunol. 93, 567-74 (1994).
15. Bachert C., K. Hörmann, R. Mösges, G. Rasp, H. Riechelmann, R. Müller, H. Luckhaupt, B.A. Stuck, C. Rudack: An update on the diagnosis and treatment of sinusitis and nasal polyposis. Allergy 58, akzeptiert zur Publikation (2003).
16. Corey J.P., R.E. Adham, A.H. Abbass, I. Seligman: The role of IgE-mediated hypersensitivity in otitis media with effusion. Am. J. Otolaryngol. 15, 138-144 (1994).
17. McColley S.A., J.L. Carroll, S. Curtis, G.M. Loughlin, H.A. Sampson: High prevalence of allergic sensitization in children with habitual snoring and obstructive sleep apnea. Chest 111, 170-173 (1997).
18. Bolger W.E., D.W. Kennedy: Nasal endoscopy in the outpatient clinic. Otolaryngol. Clin. North Am. 25, 791-802 (1992).
19. Dreborg S.: The skin prick test in the diagnosis of atopic allergy. J. Am. Acad. Dermatol. 21, 820-821 (1989).
20. Merget R., G. Schultze-Werninghaus: Allergiehauttest trotz antiallergischer Therapie. Dtsch. Med. Wochenschr. 108, 1250-1253 (1983).
21. Kersten W., P.-G. Von Wahl, C.E. Lange, J. Wenning: Empfehlungen zur In-vitro-Diagnostik allergischer Erkrankungen. Allergo J. 9, 21-26 (2000).
22. Renz H., W.-M. Becker, J. Bufe, J. Kleine-Tebbe, M. Raulf-Heimsoth, J. Saloga, T. Werfel, M. Worm: In-vitro-Allergiediagnostik. Positionspapier der DGAI. Allergo J. 11, 492-506 (2002).
23. Bachert C., D. Berdel, H. Enzmann, E. Fuchs, E. Gonsior, D. Hofmann, H. Keller, U. Nitz, R. Rudolph, W. Rüdiger, W.W. Schlenter: Richtlinien für die Durchführung von nasalen Provokationtests mit Allergenen bei Erkrankungen der oberen Luftwege. Allergologie 13, 53-55 (1990).
24. Riechelmann H., C Bachert, O. Goldschmidt, B. Hauswald, L. Klimek, W. Schlenter, A. Tasman, M. Wagenmann: Durchführung des nasalen Provokationstests bei Erkrankungen der oberen Atemwege - Positionspapier der Deutschen Gesellschaft für Allergologie und klinische Immunologie (Sektion HNO) gemeinsam mit der Arbeitsgemeinschaft Klinische Immunologie, Allergologie und Umweltmedizin der Deutschen Gesellschaft für HalsNasen-Ohrenheilkunde, Kopf- und Hals-Chirurgie. Allergologie 25, 489-496 und Allergo J. 11, 29-36 (2002).
25. Riechelmann H., C Bachert, O. Goldschmidt, B. Hauswald, L. Klimek, W. Schlenter, A. Tasman, M. Wagenmann: Durchführung des nasalen Provokationstests bei Erkrankungen der oberen Atemwege - Positionspapier der Deutschen Gesellschaft für Allergologie und klinische Immunologie (Sektion HNO) gemeinsam mit der Arbeitsgemeinschaft Klinische Immunologie, Allergologie und Umweltmedizin der Deutschen Gesellschaft für HalsNasen-Ohrenheilkunde, Kopf- und Hals-Chirurgie. Allergologie 25, 489-496 und Allergo J. 11, 29-36 (2002).
26. de Weck A.L.: Diagnostic approaches to allergy. Int. Arch. Allergy Immunol. 101, 346-351 (1993).
27. Malm L., R. Gerth van Wijk, C. Bachert: Guidelines for nasal provocations with aspects on nasal patency, airflow and airflow resistance. International Committee on Objective Assessment of the Nasal Airways, International Rhinologic Society. Rhinology 38, 1-6 (2000).
28. Hansen B., N. Mygind: How often do normal persons sneeze and blow the nose? Rhinology 40, 10-12 (2002).
29. Bachert C. und die Konsensusgruppe: Die nasale Hyperreaktivität-die allergische Rhinitis und ihre Differentialdiagnosen. Allergologie 20, 39-52 (1997).
30. Goldschmidt O., R. Mösges, L. Klimek, B. Hauswald, A. Schapowal: Die Reaktion der Nasenschleimhaut bei gesunden Probanden auf Histaminprovokation. Allergologie 21, 141-149(1998).
31. Riechelmann H.: Umweltmedizin in der HNO-Heilkunde. Laryngorhinootologie 79, 100-127 (2000).
32. Riechelmann H.: Klinische Differentialdiagnose der chronischen Rhinopathie. Allergo J. 10, 386-395 (2001).
33. Juniper E.F., G.H. Guyatt: Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin. Exp. Allergy 21, 77-83 (1991).
34. Bousquet J., M. Bullinger, C. Fayol, P. Marquis, B. Valentin, B. Burtin: Assessment ofquality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J. Allergy Clin. Immunol. 94, 182-188 (1994).
35. Neumann Y., M. Bullinger, B. Przybilla: Quality of life in allergic rhinitis: standardisation of a self-assessment questionnaire. Allergy 47 (Suppl. 12), 72 (1992).
36. Carlsson A.M.: Assessment ofchronic pain. 1. Aspects of the reliability and validity of the visual analogue scale. Pain 16, 87-101 (1983).
37. Klimek L.: Allergenkarenz. In: Klimek L. H. Riechelmann, J. Saloga, W. Mann, J. Knop: Allergologie und Umweltmedizin. Schattauer, Stuttgart 1997.
38. Frederick J.M., J.O. Warner, W.J. Jessop, I. Enander, J.A. Warner: Effect of a bed covering system in children with asthma and house dust mite hypersensitivity. Eur. Respir. J. 10, 361-366 (1997).
39. Ehnert B., S. Lau-Schadendorf, A. Weber, P. Buettner, C. Schou, U. Wahn: Reducing domestic exposure to dust mite allergen reduces bronchial hyperreactivity in sensitive children with asthma. J. Allergy Clin. Immunol. 90, 135-138 (1992).
40. Holopainen E., A. Backman, O.P. Salo: Effect of disodium cromoglycate on seasonal allergic rhinitis. Lancet 1, 55-57 (1971).
41. Blair H., R.L. Herbert: Treatment of seasonal allergic rhinitis with 2 percent sodium cromoglycate (BP) solution. Clin. Allergy 3, 283-288 (1973).
42. Craig S., E. Rubinstein, R.E. Reisman, C.E. Arbesman: Treatment of ragweed hay fever with intranasally administered disodium cromoglycate. Clin. Allergy 7, 569-576 (1977).
43. Schata M., W. Jorde, U. Richarz-Barthauer: Levocabastine nasal spray better than sodium cromoglycate and placebo in the topical treatment of seasonal allergic rhinitis. J. Allergy Clin. Immunol. 87, 873-878 (1991).
44. Bousquet J., I. Chanal, M.C. Alquie, D. Charpin, A. Didier, J. Germouty, P. Greillier, M.H. Ickovic, Y. Maria, F. Montane et al.: Prevention of pollen rhinitis symptoms: comparison of fluticasone propionate aqueous nasal spray and disodium cromoglycate aqueous nasal spray. A multicenter, double-blind, double-dummy, parallel-group study. Allergy 48, 327-333 (1993).
45. Fisher W.G.: Comparison of budesonide and disodium cromoglycate for the treatment of seasonal allergic rhinitis in children. Ann. Allergy 73, 515-520 (1994).
46. Ruhno J., J. Denburg, J. Dolovich: Intranasal nedocromil sodium in the treatment of ragweed-allergic rhinitis. J. Allergy Clin. Immunol. 81, 570-544 (1988).
47. Leino M., C. Carlson, E. Jaanio, T. Koivunen, H. Lavikkala, K. Riihela, E. Takalo: Double-blind group comparative study of 2% nedocromil sodium eye drops with placebo eye drops in the treatment of seasonal allergic conjunctivitis. Ann. Allergy 64, 398-402 (1990).
48. Ciprandi G., V. Ricca, M. Tosca, M. Landi, G. Passalacqua, G.W. Canonica: Continuous antihistamine treatment controls allergic inflammation and reduces respiratory morbidity in children with mite allergy. Allergy 54, 358-365 (1999).
49. Bachert C: The role of histamine in allergic disease: reappraisal of its inflammatory potential. Allergy 57, 287-296 (2001).
50. 1-Antihistaminika im Vergleich. Allergologie 26, 24-32 (2003).
51. Bousquet J., P. van Cauwenberge et al.: Requirements for medications commenly used in the treatment ofallergic rhinits. Allergy 58, akzeptiert zur Publikation 2003.
52. Bonsmann U., C. Bachert, K.W. Delank, P. Rohdewald: Presence of fluticasone propionate on human nasal mucosal surface and in human nasal tissue over a period of 24 h after intranasal application. Allergy 56, 532-535 (2001).
53. Passalacqua G., M. Albano, G.W. Canonica, C. Bachert, P. Van Cauwenberge, R.J. Davies, S.R. Durham, K. Kontou-Fili, F. Horak, H.J. Malling: Inhaled and nasal corticosteroids: safety aspects. EAACI Position Paper. Allergy 55, 16-33 (2000).
54. Minshall E., O. Ghaffar, L. Cameron, F. O'Brien, H. Quinn, J. Rowe-Jones, R.J. Davies, A. Prior, V.J. Lund, I.S. Mackay, K. Nolop, B. Lutsky, S.R. Durham, Q. Hamid: Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol. Head Neck Surg. 118, 648-654 (1998).
55. Rachelefsky G., P. Chervinsky, E. Meltzer, R. Morris, J. Seltzer, D. Skoner: An evaluation of the effects of beclomethasone dipropionate on longterm growth in children. J. Allergy Clin. Immunol. 101, 236 (1998).
56. Skoner D.P., G.S. Rachelefsky, E.O. Meltzer, P. Chervinsky, R.M. Morris, J.M. Seltzer, W.W. Storms, R.A. Wood: Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics 105, E23 (2000).
57. Sharek P.J., D.A. Bergman: The effect of inhaled steroids on the linear growth of children with asthma: a meta-analysis. Pediatrics 106, E8 (2000).
58. Mygind N., L.C. Laursen, R. Dahl: Systemic corticosteroid treatment for seasonal allergic rhinitis: a common, but poorly understood therapy. Allergy 55, 11-15 (2000).
59. Laursen L.C., P. Faurschou, H. Pals, U.G. Svendsen, B. Weeke: Intramuscular betamethasone dipropionate vs. oral prednisolone in hay fever patients. Allergy 42, 168-172 (1987).
60. Meltzer E.O., K. Malmstrom, S. Lu, B.M. Prenner, L.X. Wei, S.F. Weinstein, J.D. Wolfe, T.F. Reiss: Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J. Allergy Clin. Immunol. 105, 917-922 (2000).
61. Pullerits T., L. Praks, B.E. Skoogh, R. Ani, J. Lotvall: Randomized placebo-controlled study comparing a leukotriene receptor antagonist and a nasal glucocorticoid in seasonal allergic rhinitis. Am. J. Respir Crit Care Med. 159, 1814-1818 (1999).
62. Wilson A.M., L.C. Orr, E.J. Sims, B.J. Lipworth: Effects of monotherapy with intranasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clin. Exp. Allergy 31, 61-68 (2001).
63. Horak F., J. Toth, B. Marks, U.P. Stubner, U.E. Berger, S. Jager, B. Burtin, C. Duby: Efficacy and safety relative to placebo of an oral formulation of cetirizine and sustained-release pseudoephedrine in the management of nasal congestion. Allergy 53, 849-856 (1998).
64. Corren J., A. G. Harris, D. Aaronson, W. Beaucher, R. Berkowitz, E. Bronsky, R. Chen, P. Chervinsky, R. Cohen, J. Fourre, J. Grossman, E. Meltzer, A. Pedinoff, W. Stricker, A. Wanderer: Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. J. Allergy Clin. Immunol. 100, 781-788 (1997).
65. Graf P., H. Hallen, J.E., Juto: Four-week use of oxymetazoline nasal spray (Nezeril) once daily at night induces rebound swelling and nasal hyperreactivity. Acta Otolaryngol. 115, 71-75 (1995).
66. Kaiser H.B., S.R. Findlay, J.W. Georgitis, J. Grossman, P.H. Ratner, D.G. Tinkelman, P. Roszko, E. Zegarelli, C.C. Wood: Long-term treatment of perennial allergic rhinitis with ipratropium bromide nasal spray 0.06%. J. Allergy Clin. Immunol. 95, 1128-1132 (1995).
67. Dolovich J., L. Kennedy, F. Vickerson, F. Kazim: Control of the hypersecretion ofvasomotor rhinitis by topical ipratropium bromide. J. Allergy Clin. Immunol. 80, 274-278 (1987).
68. Weiser M., L.H. Gegenheimer, P. Klein: A randomized equivalence trial comparing the efficacy and safety of Luffa comp.-Heel nasal spray with cromolyn sodium spray in the treatment of seasonal allergic rhinitis. Forsch. Komplementarmed. 6, 142-148 (1999).
69. Davies A., G. Lewith, J. Goddard, P. Howarth: The effect of acupuncture on nonallergic rhinitis: a controlled pilot study. Altern. Ther. Health Med. 4, 70-74 (1998).
70. Xue C.C., R. English, J.J. Zhang, C. Da Costa, C.G. Li: Effect of acupuncture in the treatment of seasonal allergic rhinitis: a randomized controlled clinical trial. Am. J. Clin. Med. 30, 1-11 (2002).
71. Dorsch W., J. Ring: Komplementärmethoden bzw. sogenannte Alternativmethoden in der Allergologie. Allergologie 25, 539-547 (2002).
72. Casale T.B., I.L. Bernstein, W.W. Busse, C.F. LaForce, D.G. Tinkelman, R.R. Stoltz, R.J. Dockhorn, J. Reimann, J.Q. Su, R.B. Fick Jr, D.C. Adelman: Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J. Allergy Clin. Immunol. 100, 110-121 (1997).
73. Adelroth E., E. Rak, T. Haahtela, G. Aasand, L. Rosenhall, O. Zetterstrom, A. Byrne, K. Champain, J. Thirlwell, G.D. Cioppa, T. Sandstrom: Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J. Allergy Clin. Immunol. 106, 253-259 (2000).
74. Kuehr J., J. Brauburger, S. Zielen, U. Schauer, W. Kamin, A. Von Berg, W. Leupold, K.C. Bergmann, C. Rolinck-Werninghaus, M. Grave, T. Huhsch, U. Wahn: Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J. Allergy Clin. Immunol. 109, 274-280 (2002).
75. Bousquet J., R. Lockey, H. Malling: WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 53 (Suppl. 44), SI-S42 (1998).
76. Donahue J.G., D.K. Greineder, L. Connor-Lacke, C.F. Canning, R. Platt: Utilization and cost of immunotherapy for allergic asthma and rhinitis. Ann. Allergy Asthma Immunol. 82, 339-347 (1999).
77. Moller C., S. Dreborg, H.A. Ferdousi, S. Halken, A. Host, L. Jacobsen, A. Koivikko, D.Y. Koller, B. Niggemann, L.A. Norberg, R. Urbanek, E. Valovirta, U. Wahn: Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J. Allergy Clin. Immunol. 109, 251-256 (2002).
78. Des Roches A., L. Paradis, J. Knani, A. Hejjajoui, H. Dhivert, P. Chanez, J. Bousquet: Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of efficacy of immunotherapy after its cessation. Allergy 51, 430-433 (1996).
79. Purello-D'Ambrosio E., S. Gangemi, R.A. Merendino, S. Isola, P. Puccinelli, S. Parmiani, L. Ricciardi: Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin. Exp. Allergy. 31, 1295-1302 (2001).
80. Pajno G.B., G. Barberio, F. De Luca, L. Morabito, S. Parmiani: Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin. Exp. Allergy 31, 392-397 (2001).
81. Pichler C.E., A. Helbling, W.J. Pichler: Three years of specific immunotherapy with house dust mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of nonspecific bronchial hyperre-activity. Allergy 56, 301-306 (2001).
82. Kleine-Tebbe J., T. Fuchs, L. Klimek, J. Kuhr, U. Lepp, B. Niggemann, J. Rakoski, H. Renz, J. Saloga, J. Simon: Die spezifische Immuntherapie (Hyposensibilisierung) mit Allergenen. Allergologie 24, 535-544 (2001).
83. Sennekamp J., T. Fuchs, B. Hornung, W. Kersten, L. Klimek, W. Leupold, H. Merk, W. Rebien: Empfehlungen zur praktischen Durchführung der spezifischen Immuntherapie mit Allergenen (Hyposensibilisierung). Allergo J. 11, 332-338 (2002).
84. Brown J.L., A.J Frew: The efficacy of oromucosal immunotherapy in respiratory allergy. Clin. Exp. Allergy 31, 8-10 (2001).
85. Mori S., S. Fujieda, M. Igarashi, G.K. Fan, H. Saito: Submucous turbinectomy decreases not only nasal stiffness but also sneezing and rhinorrhea in patients with perennial allergic rhinitis. Clin. Exp. Allergy 29, 1542-1548 (1999).